Funded in part by Abbott Laboratories
No effect of magnesium supplementation on metabolic control and insulin sensitivity in type 2 diabetic patients with normomagnesemia
Navarrete-Cortes A, Ble-Castillo JL, Guerrero-Romero F, Cordova-Uscanga R, Juárez-Rojop IE, Aguilar-Mariscal H, Tovilla-Zarate CA, Lopez-Guevara Mdel R
Magnesium research · 40 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- Abbott Laboratories
- University or hospital
- Universidad Juárez Autónoma de Tabasco
Based on 2 listed funder(s).
Publication
- Published
- 2014-04-01 · Magnes Res · vol. 27 · issue 2 · pp. 48–56
- Publisher
- John Libbey Eurotext
- Cited
- 56 citations · more than 83% of similar papers · 1.8× the field average
- References
- 0 works
- Access
- Paywalled
- Research areas
- Parathyroid Disorders and Treatments · Magnesium in Health and Disease · Biomedical Research and Pathophysiology
- Keywords
- Placebo, Internal medicine, Medicine, Magnesium, Type 2 diabetes, Crossover study, Insulin, Endocrinology, Diabetes mellitus, Insulin sensitivity, Randomized controlled trial, Insulin resistance, Chemistry
- MeSH
- humans, diabetes mellitus, type 2, insulin resistance, magnesium, treatment outcome, cross-over studies, double-blind method, dietary supplements, adult, aged, middle aged, female, male
8 authors
From MX
- Adrián Navarrete-CortesHospital General De Zona
- Jorge L. Blé‐CastilloUniversidad Juárez Autónoma de Tabasco
- Fernando Guerrero‐RomeroMexican Social Security Institute
- Rubén Córdova-UscangaUniversidad Juárez Autónoma de Tabasco
- Isela Esther Juárez‐RojopUniversidad Juárez Autónoma de Tabasco
- Hidemí Aguilar-MariscalUniversidad Juárez Autónoma de Tabasco
Abstract
There are limited and conflicting data from clinical trials concerning the beneficial effects of magnesium supplementation on diabetic patients. We investigated the effects of magnesium supplementation on metabolic control and insulin sensitivity in type 2 diabetic patients with normomagnesemia. A total of 98 normomagnesemic subjects with type 2 diabetes were enrolled in a randomized, crossover, double-blind, placebo-controlled trial. Participants were randomly assigned to receive magnesium lactate (360 mg elemental magnesium) or placebo for three months, followed by a three-month washout period. Treatment assignments were then reversed over an additional three months of follow-up. The primary endpoint was a reduction in fasting glucose and HbA1c. A total of 56 subjects completed the follow-up in the magnesium and placebo supplementation groups. Urinary magnesium excretion was increased following magnesium supplementation in the intervention group compared with the placebo group (p = 0.0002). Fasting glucose, HbA1c, insulin and HOMA-IR, as well as lipid profile, did not change significantly during treatment. We concluded that magnesium supplementation does not improve metabolic control or insulin sensitivity in diabetic subjects with normomagnesemia.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.